Drug Profile


Alternative Names: CI 1008; Isobutylgaba; Lyrica; PD 144723; Pregabalin oral solution

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwestern University
  • Developer Eisai Co Ltd; Pfizer
  • Class Aminobutyric acids; Analgesics; Antiepileptic drugs; Anxiolytics; Neuroprotectants; Small molecules
  • Mechanism of Action CACNA2D1 protein modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Fibromyalgia; Generalised anxiety disorder; Neuropathic pain; Partial epilepsies; Postherpetic neuralgia
  • Phase III Tonic-clonic epilepsy
  • Discontinued Pain; Postoperative pain; Restless legs syndrome

Most Recent Events

  • 08 Jun 2017 Pregabalin launched for Fibromyalgia and Neuropathic pain (PO, orally disintegrating) in Japan
  • 18 Feb 2017 Launched for Fibromyalgia in Japan (PO, Tablet)
  • 18 Feb 2017 Launched for Neuropathic pain in Japan (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top